Lytix Biopharma (LYTIX) investor relations material

Executive summary

• Ruxotemitide demonstrated strong anti-tumor activity, durable responses, and systemic immune activation in melanoma and basal cell carcinoma, both as monotherapy and in combination with pembrolizumab, with favorable safety and abscopal effects in non-injected tumors.

• NeoLIPA phase II neoadjuvant melanoma study interim results showed up to 100% pathological complete response in some patients, 88% overall pathological response, and 55% major pathological response, surpassing benchmarks from comparable studies.

• Partnership with Verrica in basal cell carcinoma yielded strong phase II results, with a phase III registrational trial planned for 2026.

• Strategic focus remains on advancing ruxotemitide to registrational studies in melanoma and BCC, and expanding the pipeline with LTX-401.

• Two successful capital raises in Q1 2026 provided NOK 77.3 million, strengthening financial flexibility for clinical and commercial activities.

Financial highlights

• Q1 2026 operating expenses were NOK 27 million, up from NOK 13 million in Q1 2025, mainly due to increased R&D and strategic activity.

• Cash and short-term financial investments totaled NOK 120 million at quarter-end, following NOK 77 million in capital raised.

• Total liabilities decreased to NOK 14 million at end of Q1 2026 from NOK 34.9 million at end of Q1 2025.

• Loss for the period was NOK 25,945 thousand in Q1 2026, reflecting increased operational activity.

• Current cash position is expected to fund operations through the first half of 2027.

Outlook and guidance

• NeoLIPA top-line results expected in the second half of 2026; enrollment at 74–75% with new clinical sites opened.

• FDA meeting on registrational trial design for neoadjuvant melanoma scheduled for the second half of 2026.

• Registrational study of ruxotemitide plus anti-PD-1 in melanoma planned to start in 2027, contingent on FDA alignment and NeoLIPA data.

• Verrica partnership to initiate Phase III BCC trial in 2026.

• LTX-401 clinical entry targeted for 2027.